Invention Grant
- Patent Title: Small molecule conjugates specifically activated in tumor microenvironment for targeting and use thereof
-
Application No.: US15505861Application Date: 2015-08-21
-
Publication No.: US10682371B2Publication Date: 2020-06-16
- Inventor: Chen Liu , Yuan Liu
- Applicant: Yafei Shanghai Biolog Medicine Science & Technology Co. Ltd.
- Applicant Address: CN Shanghai
- Assignee: YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOGY CO. LTD.
- Current Assignee: YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOGY CO. LTD.
- Current Assignee Address: CN Shanghai
- Agency: Knobbe, Martens, Olson & Bear LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@77e8e788 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@13e3d989 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@74998848 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@35ec31cf com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@508545d com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@8aafae4
- International Application: PCT/CN2015/087746 WO 20150821
- International Announcement: WO2016/026458 WO 20160225
- Main IPC: A61K31/7072
- IPC: A61K31/7072 ; A61K47/65 ; A61K47/54 ; A61K31/7076 ; A61K31/4745 ; A61K31/7068 ; A61K31/337 ; A61P35/00 ; A61K31/136 ; A61K31/198 ; A61K31/427 ; A61K31/475 ; A61K31/505 ; A61K31/519 ; A61K31/704 ; A61K31/7048

Abstract:
Provided is an anticancer compound including a cleavable linker specifically activated in a tumor microenvironment, and use thereof. The anticancer compound is represented by the following formula, wherein, R1 is a normal functional group or a protection group; R2 is Ala, Thr, Val or Ile; R3 is Ala, Val or Asn; R4 is a drug group linked via a hydroxyl group or an amino group; and the general formula of the drug is R4H. The anticancer compound is only activated at a local portion of a tumor, thus avoiding the defect of immune system damage of a traditional chemotherapeutic drug, and promoting tumor immunization by removing a tumor immunosuppression cell. The anticancer compound or pharmaceutical composition thereof is jointly used with immunotherapy, thus improving the effect of treating the tumor, and effectively inhibiting tumor metastasis and osseous metastasis.
Public/Granted literature
- US20170266308A1 SMALL MOLECULE CONJUGATES SPECIFICALLY ACTIVATED IN TUMOR MICROENVIROMENT FOR TARGETING AND USE THEREOF Public/Granted day:2017-09-21
Information query
IPC分类: